Long-Term Side Effects of Mounjaro — UK Health Information

Mounjaro was approved by the MHRA in 2023, so genuine long-term data (beyond 2+ years) is still emerging. The SURMOUNT clinical trials — which evaluated tirzepatide for weight management — ran for up to 72 weeks. This provides moderate-term evidence, but not multi-year data yet.

What we know so far:

• Most gastrointestinal side effects (nausea, diarrhoea, vomiting) occur within the first 4–12 weeks and tend to improve as the body adjusts
• Appetite suppression — the desired effect — appears to persist throughout treatment
• Hair loss (alopecia) has been reported but may relate to gradual weight management rather than the tirzepatide itself
• Injection site reactions are generally mild and reduce with repeated use
• Pancreatitis risk remains rare but requires immediate medical attention if severe abdominal pain develops

Your GP can discuss your individual risk profile and whether this medication suits your long-term weight management plan.

Some users report that certain side effects change rather than disappear with prolonged use. Persistent nausea, reduced appetite beyond what feels healthy, and occasional stomach discomfort have been reported by long-term users. Gallstone formation and gallbladder pain are uncommon but have occurred during extended use — if you develop pain in your upper right abdomen, contact your GP immediately.

Because tirzepatide slows gastric emptying, some people experience ongoing indigestion or reflux. Fatigue and dizziness tend to resolve within weeks, but occasional reports of dizziness persist in some users. The dose titration schedule — increasing your Mounjaro dose every 4 weeks — may trigger temporary side effect recurrence at each escalation step. If side effects become unmanageable, your prescriber can pause dose increases or adjust your treatment plan.

Because tirzepatide slows gastric emptying, some people experience ongoing indigestion or reflux. Fatigue and dizziness tend to resolve within weeks, but occasional reports of dizziness persist in some users. The dose titration schedule — increasing your Mounjaro dose every 4 weeks via the KwikPen device — may trigger temporary side effect recurrence at each escalation step. If side effects become unmanageable, your prescriber can pause dose increases or adjust your treatment plan. Using our GLP-1 weight loss calculator can help you estimate expected outcomes, which may help inform discussions with your prescriber about whether to continue at your current dose or escalate further.

Stopping Mounjaro: If you stop tirzepatide, appetite typically returns over 2–4 weeks. There is no evidence of dependence, but weight regain is common without sustained lifestyle changes. This is why weight management medication works best alongside continued diet and exercise.

Monitoring: If you use Mounjaro long-term, your prescriber will want to monitor your health periodically — including checking for signs of pancreatitis, gallbladder issues, and changes in blood sugar if you have diabetes. Some people also report changes in how medications (including oral contraceptives) are absorbed — inform your GP of all medicines you take.

Eligibility and access: NHS specialist weight management services and private prescribers can assess whether long-term use is appropriate for you. Remember that Mounjaro works best alongside a reduced-calorie diet and increased physical activity.